![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Deccan Digoxin](https://www.pharmacompass.com/image/flap/deccan-digoxin-headergif-13818.gif)
![Deccan Digoxin](https://www.pharmacompass.com/image/flap/deccan-digoxin-mobile-headergif-6946.gif)
Active Filter(s):
Details:
Digoxin tablets which is inhibiting Na-K ATPase, indicated for the treatment of mild to moderate heart failure in adults, increases myocardial contractility in pediatric patients with heart failure.
Lead Product(s): Digoxin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lanoxin-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022